Prostate Health: An Evidence-Based Appraisal of Enlargement, Supplements, and Cancer Treatment

The Full Evidence-Based Picture of Prostate Health

Bottom line

No single supplement or treatment can address every aspect of prostate health. Sound interpretation requires distinguishing the disease type, study population, and clinical endpoint, then using high-level human evidence to weigh benefits, harms, and remaining uncertainties. PMID: 36912538

Benign prostatic hyperplasia: causes cannot be inferred by intuition

Benign prostatic enlargement, or hyperplasia, has a well-defined biological and pathological context. Major associated factors identified in current reviews include aging, androgen signaling, inflammation, and metabolic factors. There is therefore insufficient evidence to claim that urination posture directly causes benign prostatic hyperplasia. This accords with Professor Lin’s central reminder in the original article: physiological plausibility does not establish causation. PMID: 30943489

Peanut root does contain resveratrol, but “containing a compound” and “treating a disease when consumed” are entirely different propositions. Existing research on peanut root remains largely confined to mouse models and mechanistic work. Even if animal experiments show a signal, they cannot directly demonstrate improvement in urinary symptoms or prostate volume in humans. Professor Lin’s skepticism about peanut root as a treatment for benign prostatic hyperplasia therefore remains consistent with the continuing lack of human clinical trials. PMID: 42016224

Likewise, the research identified for a product called Multiple Solanum concerns in vitro or ex vivo mechanisms. It cannot be presented as proof from human clinical trials that the product improves urinary function impaired by benign prostatic hyperplasia. Within the evidence reviewed here, it also remains unestablished whether lycopene supplements can prevent prostate cancer. PMID: 29111778

DHEA and testosterone: distinguish precursor biology, treatment, and cancer risk

DHEA is a human hormone precursor that can be further converted into androgen and estrogen derivatives; this basic physiological description is consistent with Professor Lin’s original article. Yet the ability to undergo physiological conversion does not mean supplementation necessarily provides health benefits, nor does it mean that every proposed risk has been confirmed in human studies. Functional benefits in generally older adults remain inconclusive. Although some treatment outcomes show signals of improvement in selected infertility populations, live-birth rates did not increase. The more accurate conclusion is therefore that benefits vary by population and endpoint and cannot be described as universally favorable. PMID: 22032408 PMID: 21649617 PMID: 35996249

Potential harms of DHEA supplementation also require precise wording. A meta-analysis of randomized trials supports unfavorable lipid changes, including reduced HDL; however, the literature collected by ECU did not directly establish an inevitable increase in prostate, breast, or ovarian cancer risk. Existing signals warrant caution, but mechanistic hypotheses should not be rewritten as proven cancer causation. PMID: 32675010

Professor Lin’s historical article took a strictly cautious position on supplemental testosterone and prostate cancer risk. The literature has since been updated: among appropriately screened men without known prostate cancer who have confirmed symptomatic testosterone deficiency, newer pooled evidence has not shown an increase in prostate cancer events over the short to medium term. This is a refinement of the applicable scope as science advances. It does not recast testosterone as something that may be supplemented indiscriminately, nor does it eliminate uncertainty about long-term risk or use in patients with previous or active prostate cancer. PMID: 41673435 PMID: 32409202

Clinical safety thresholds remain essential. Testosterone therapy should be limited to patients with symptoms and repeatedly confirmed deficiency, with prostate risk assessed and monitored before and after treatment. Risk assessment and monitoring do not mean the therapy has been proven to cause cancer; they are necessary components of responsible medical care. Testosterone therapy is also not an established treatment for prostate cancer, and its use in survivors of high-risk cancer remains investigational. PMID: 34390882 PMID: 31420972 PMID: 30244116

Foods, vitamins, and “cancer prevention” claims

Turning findings from cultured cells or mouse tumors into cancer-prevention advice for humans is a common evidentiary leap. The original research on ursolic acid, curcumin, and resveratrol used cells and mouse xenograft tumor models, testing individual compounds and pairwise combinations. It did not show that eating all three foods together prevents prostate cancer in humans. Professor Lin criticized the media for jumping from compounds and mouse findings to cancer-prevention claims about foods; that criticism is consistent with the study design. PMID: 29202102

Nor can supplements be presumed safe and effective merely because they are described as antioxidants. A large randomized trial found that vitamin E supplementation increased prostate cancer risk in healthy men. The finding reminds us that supplements can exert genuine biological effects—and that genuine effects can be harmful. PMID: 21990298

Selenium supplements have not been shown to prevent cancer. Conversely, the claim that “selenium universally increases every cancer” goes beyond the evidence. The available data are better described as showing no cancer-prevention benefit, with possible signals of harm at particular doses, under particular baseline conditions, or for particular outcomes—not as a comprehensive causal declaration applying to everyone. PMID: 29376219

Dietary associations likewise should not be overextended. Among patients with prostate cancer, poultry with skin and eggs have been associated with signals of progression risk, while later research found more favorable associations when poultry or fish replaced red meat. Whether the poultry had skin was not established as the decisive explanation in the later study. Total dairy intake was not associated with a significant increase in death from all cancers, whereas higher whole-milk intake in men was positively associated with death from prostate cancer. These observations can inform risk discussions but should not be reduced to a claim that a single food inevitably causes cancer. PMID: 20042525 PMID: 27651069 PMID: 27765039

Localized prostate cancer: consider death, metastasis, and quality of life together

The importance of the ProtecT trial is not that it declared treatment useless, but that it allowed patients to see the tradeoffs among different endpoints. At ten years of follow-up, prostate cancer mortality was very low in the active-monitoring, surgery, and radiotherapy groups, with no significant difference among them. At fifteen years, the mortality difference remained small. These later findings update the question Professor Lin raised while awaiting long-term data, while preserving his caution against deciding whether to treat solely on the basis of mortality. PMID: 27626136 PMID: 36912538

Similar mortality does not, however, make the strategies identical. Surgery and radiotherapy can reduce metastasis or progression, but each carries quality-of-life costs. Surgery causes greater and potentially lasting harm to urinary continence and sexual function, while radiotherapy may worsen bowel function and cause rectal bleeding. Reasonable shared decision-making should place tumor risk, metastatic potential, personal values, and tolerance of adverse effects on the same mental map instead of treating “how long will I live?” as the only question. PMID: 27626365 PMID: 36912538

Advanced treatment: first identify the endpoint the trial actually measured

Apalutamide is an androgen-receptor inhibitor that can delay metastasis or symptomatic progression in nonmetastatic castration-resistant prostate cancer. The pivotal endpoint in the original trial was metastasis-free survival, not overall survival. An extension of time without metastasis therefore cannot be directly rewritten as a demonstrated extension of life. The drug has clinical value, but that value must be described using the endpoint the study actually measured. PMID: 29420164

How to use this evidence

When evaluating a claim about prostate care or treatment, ask in sequence: Was the research conducted in cells, animals, or humans? Does it show an observational association or report a randomized trial? Does the study population resemble the person to whom the claim is being applied? Did the study measure symptoms, metastasis, cancer death, overall death, or a surrogate endpoint? What adverse effects accompany any benefit? This approach preserves the central stance of Professor Lin’s original article—exposing exaggerated promotion—while allowing the boundaries of conclusions to be adjusted in the language of scientific progress when the literature has evolved.